Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 14/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 14/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.67 |
| ▸ | F7 | P08709 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.63 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.63 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.63 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855339 | 1.00 | MKNK1 (1.00) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL27521530 | 0.86 | MKNK1 (0.74) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL27605181 | 0.85 | MKNK1 (0.76) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4508905 | 0.84 | MKNK1 (0.71) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL208351 | 0.83 | MKNK1 (1.00) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29788154 | 0.83 | MKNK1 (1.00) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL28305277 | 0.83 | MKNK1 (0.71) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL13188346 | 0.82 | MKNK1 (0.77) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL608617 | 0.82 | KMO (0.73) | MKNK1MKNK2CHEK2F7F3 | |
| SCHEMBL30108236 | 0.82 | MKNK1 (0.77) | MKNK1MKNK2CHEK2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| US-9937168-B2 | Nicotine-containing pharmaceutical compositions | NICONOVUM USA, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20170326138-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2017-11-16 | — | — | US | claimed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | claimed |
| WO-2009125923-A2 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | WO | claimed |
| EP-2108649-A1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | Korea Research Institute of Chemical Technology (KR) | 2009-10-14 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | ROSSI CRISTINA | 2008-08-28 | — | — | US | claimed |
| EP-1868997-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-26 | — | — | EP | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| WO-2006097460-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | MKNK1 715/4885MKNK2 933/4885CHEK2 1684/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | MKNK1 1785/4885MKNK2 1469/4885CHEK2 871/4885 |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | HDAC1, HDAC8, HDAC9 | MKNK1 2355/4885MKNK2 2349/4885CHEK2 1463/4885 |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | HTR2C, HTR5A, HTR2A | MKNK1 4008/4885MKNK2 3356/4885CHEK2 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.